L. Nicolas Gonzalez Castro, Md, Phd

This phase 2 trial tests a combination of three drugs—pembrolizumab (immunotherapy), olaparib (a targeted therapy), and temozolomide (chemotherapy)—in people with recurrent glioblastoma, a type of brain tumor that has come back after initial treatment. The study will enroll 78 ad…